Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
Z5CNETeGQv9EQStC
